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An ES cell caution
 
ny cell therapy risks introducing mutated and possibly 
tumorigenic cells. Now results from Peter Stambrook 
(University of Cincinnati, Cincinnati, OH) and colleagues 
underline this concern for embryonic stem (ES) cells, which 
are one possible source for therapeutic cells.
Stambrook constructed a cell line in which he could detect 
loss or mutation of a heterozygous marker gene. Loss (rather 
than mutation) of the functional allele was the proximate 
cause in 
 
 
 
80% of the events with both mouse embryonic 
fibroblasts (MEFs) and ES cells. But marker-deficient colonies 
arose 400-times faster in MEFs than in ES cells—good news for 
ES cell proponents.
But a closer look revealed complications. Whereas all the 
loss events in MEFs were caused by mitotic recombination, a 
full 57% of the ES cell events were apparently caused by loss 
of the entire chromosome, followed by reduplication of the 
single remaining chromosome. Such events have the potential 
to uncover multiple mutant alleles on the single remaining 
chromosome, and thus pose a greater risk than a more spatially 
limited recombination event.
Does this mean that ES cells are unfit for use? Stambrook 
thinks not. “This is not an argument against using ES cells for 
A
 
therapeutic uses,” he says. “It’s 
just a caution that one should be 
aware about.” Stambrook says it 
should be possible to screen ES 
cells for chromosome loss 
events. Furthermore, the 
necessary comparisons between 
cell types have not yet been 
completed. Loss frequencies for 
adult stem cells are not yet 
known, and similar loss events 
may occur in the MEFs, but be 
masked by the more frequent mitotic recombination events.
Recombination events between nonidentical sequences 
may be suppressed in ES cells by the mismatch repair 
machinery, at least according to evidence from homologous 
recombination experiments. Before looking for a possible 
cause for increased chromosome loss in ES cells, researchers 
will need to confirm that there is indeed a difference in rates 
between ES and somatic cells. 
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A chemokine tug-of-war
 
cells 
troll for 
antigens in 
lymphoid 
organ 
follicles, 
but once 
they have 
paired up with their antigen, they need help from T cells, 
which are found in separate T-rich zones. Karin Reif, Jason 
Cyster (University of California, San Francisco, CA), and 
colleagues report that activated B cells increase their
production of CCR7, a T-zone chemokine receptor, so that 
they can migrate toward the T-rich zone. Activation of both 
CCR7 and CXCR5, the receptor for B-zone chemokines, 
strikes a balance so that the B cells end up at the border of the 
two zones.
Overexpression of the T-zone receptor CCR7 was 
sufficient to drive nonactivated B cells to the B/T border, 
whereas overexpression of the B-zone receptor CXCR5 kept 
activated B cells in the B-rich follicles. But the two chemokine 
systems are not the only determinants of B cell position. 
Cells lacking the B-zone receptor CXCR5 still localized to 
the B/T border after activation. “They’re actually being kept 
out of the center [of the T zone] by something else,” says 
Cyster. He suggests that the B cells may be less responsive 
than T cells to the T-zone chemokines, or the adhesive 
properties of the B cells and their later arrival may keep 
them layered outside of the main mass of T cells. 
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B
Chemokines direct B cells from follicles (left) 
to the B/T border (right).
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Make junction, will travel
 
adherin-based adhesion complexes can trigger actin assembly, 
according to a proposal from Eva Kovacs, Alpha Yap, and 
colleagues (University of Queensland, Brisbane, Australia). The 
actin assembly may, in turn, control how cells recognize and move 
over one another.
Kovacs and Yap began their study by observing cells moving over a 
substrate covered with E-cadherin. They noticed that clumps of 
E-cadherin colocalized with both filamentous actin and components of 
the actin-nucleating Arp2/3 complex. Similar colocalization was 
apparent upon addition of E-cadherin beads. Finally, E-cadherin 
C
 
coimmunoprecipitated with Arp2/3 
components, even in the presence of the 
actin-depolymerizing drug cytochalasin D.
The association suggests that cadherin 
ligation might trigger actin assembly by 
Arp2/3. “What we’d like to correct,” says 
Yap, “is the notion that cadherin complexes 
are solely binding to preformed actin 
filaments.” In his view, the adhesion 
machinery is no longer seen as an inert 
scaffold, but as a dynamic complex that 
drives changes in cell shape and movement. 
Beads coated with 
E-cadherin trigger 
actin assembly.
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The connection between E-cadherin and Arp2/3 may or may not be 
direct. When Yap and his colleagues know more about this interaction, 
they hope to disrupt it without interfering with cadherin adhesive 
function, thus testing the importance of the link. They will be looking 
for defects in processes such as compaction, when cell surfaces extend 
over one another. 
 
 
 
Reference: 
 
Kovacs, E.M., et al. 2002. 
 
Curr. Biol.
 
 12:379–382.
Large (left, inset) and small 
(right, inset) centromeres al-
low for detection of chromo-
some loss events in ES cells.
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